Canlyniadau Chwilio - David J. Lederer
- Dangos 1 - 20 canlyniadau o 88
- Ewch i'r Dudalen Nesaf
-
1
Selecting lung transplant candidates: where do current guidelines fall short? gan J.L. Hook, David J. Lederer
Cyhoeddwyd 2012Revisão -
2
Micromechanics of Alveolar Edema gan Carrie E. Perlman, David J. Lederer, Jahar Bhattacharya
Cyhoeddwyd 2010Artigo -
3
-
4
Frailty in Pulmonary and Critical Care Medicine gan Jonathan P. Singer, David J. Lederer, Matthew R. Baldwin
Cyhoeddwyd 2016Revisão -
5
-
6
-
7
-
8
-
9
-
10
-
11
Outcomes and Mortality Prediction Model of Critically Ill Adults With Acute Respiratory Failure and Interstitial Lung Disease gan Whitney D. Gannon, David J. Lederer, Mauer Biscotti, Azka Javaid, Nina Patel, Daniel Brodie, Matthew Bacchetta, Matthew R. Baldwin
Cyhoeddwyd 2018Artigo -
12
-
13
-
14
Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: design of a double-blind, randomised, placebo-controlled phase II trial gan Toby M. Maher, Tamera J. Corte, Aryeh Fischer, Michael Kreuter, David J. Lederer, María Molina‐Molina, Judit Axmann, Klaus-Uwe Kirchgaessler, Vincent Cottin
Cyhoeddwyd 2018Artigo -
15
Association of Angiotensin Modulators With the Course of Idiopathic Pulmonary Fibrosis gan Michael Kreuter, David J. Lederer, María Molina‐Molina, Imre Noth, Claudia Valenzuela, Lutz Frankenstein, Derek Weycker, Mark Atwood, Klaus-Uwe Kirchgaessler, Vincent Cottin
Cyhoeddwyd 2019Artigo -
16
-
17
Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function gan Carlo Albera, Ulrich Costabel, Elizabeth A. Fagan, Marilyn K. Glassberg, Eduard Gorina, Lisa Lancaster, David J. Lederer, Steven D. Nathan, Dominique Spirig, Jeff Swigris
Cyhoeddwyd 2016Artigo -
18
Obesity and Underweight Are Associated with an Increased Risk of Death after Lung Transplantation gan David J. Lederer, Jessie S. Wilt, F. D’Ovidio, Matthew Bacchetta, Lori Shah, Shankari Ravichandran, J. -L. J. Lenoir, Brenda Klein, Joshua Sonett, Selim M. Arcasoy
Cyhoeddwyd 2009Artigo -
19
Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and... gan Toby M. Maher, Michael Kreuter, David J. Lederer, Kevin K. Brown, Wim Wuyts, Nadia Verbruggen, Simone Stutvoet, Ann Fieuw, Paul Ford, Walid Abi‐Saab, Marlies Wijsenbeek
Cyhoeddwyd 2019Artigo -
20
Efficacy of Pirfenidone in the Context of Multiple Disease Progression Events in Patients With Idiopathic Pulmonary Fibrosis gan Steven D. Nathan, Ulrich Costabel, Ian Glaspole, Marilyn K. Glassberg, Lisa Lancaster, David J. Lederer, Carlos A.C. Pereira, Benjamin Trzaskoma, Elizabeth Morgenthien, Susan L. Limb, Athol U. Wells
Cyhoeddwyd 2018Artigo
Offerynnau Chwilio:
Pynciau Perthynol
Medicine
Internal medicine
Lung
Pathology
Lung transplantation
Transplantation
Idiopathic pulmonary fibrosis
Confidence interval
Surgery
Gastroenterology
Alternative medicine
Intensive care medicine
Placebo
Cardiology
Biology
Hazard ratio
Interstitial lung disease
Environmental health
Population
Asthma
Cohort
Immunology
Gene
Genetics
Pediatrics
Prospective cohort study
Body mass index
Clinical trial
Lung function
Odds ratio